Mar 1, 2026 06:49PM
Feb 9, 2026 10:34PM
Feb 6, 2026 01:04AM
Feb 5, 2026 08:31PM
Jan 25, 2026 11:52PM
Jan 25, 2026 08:37PM
Jan 12, 2026 06:50PM Eisai and Nuvation Bio Enter into Exclusive Licensing Agreement for Taletrectinib in Europe and Additional Countries Outside the U.S., China and Japan
Jan 5, 2026 07:43PM
Nov 26, 2025 06:03AM
Nov 26, 2025 04:42AM
Nov 17, 2025 07:08AM
Oct 27, 2025 12:23AM
Oct 14, 2025 03:54AM
Oct 3, 2025 04:01AM Eisai Highlights Breadth of Oncology Research at ESMO 2025
Sep 28, 2025 08:33PM
Sep 17, 2025 05:52AM
Sep 17, 2025 04:20AM
Sep 2, 2025 09:32PM
Sep 1, 2025 12:50AM
Aug 31, 2025 11:44PM
Jul 30, 2025 07:20PM New Data Presented at AAIC Demonstrates Investigational LEQEMBI(R) (lecanemab-irmb) 360 mg Subcutaneous Maintenance Dosing Could Offer a New Option for Ongoing Treatment of Early Alzheimer's Dise
Jul 30, 2025 07:10PM
Jul 16, 2025 12:50AM
May 21, 2025 01:00AM
Mar 4, 2025 02:22AM
Mar 2, 2025 10:53PM
Jan 27, 2025 06:46PM
Jan 14, 2025 07:03PM FDA Accepts LEQEMBI (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease
Nov 14, 2024 11:31PM
Oct 31, 2024 11:56PM
Oct 30, 2024 11:56PM
Sep 5, 2024 02:59AM
Aug 22, 2024 05:54AM
Aug 13, 2024 07:59PM
Aug 5, 2024 11:15PM Eisai: Update Regarding the Regulatory Status of LEQEMBI Subcutaneous Formulation
Jul 30, 2024 11:59PM
Jul 11, 2024 10:56PM
Jul 10, 2024 08:00PM
Jun 28, 2024 01:57AM
Jun 10, 2024 04:50AM
May 28, 2024 01:19AM
May 23, 2024 04:07AM Eisai Showcases Oncology Portfolio and Pipeline at ASCO 2024
May 14, 2024 09:19PM
Mar 31, 2024 07:39PM
Jan 15, 2024 07:25PM
Jan 11, 2024 01:33AM
Oct 10, 2023 11:07PM
Sep 25, 2023 01:17AM
Jul 19, 2023 09:23PM Eisai Presents Latest Analysis of Lecanemab's Effect on Biomarker Changes and Subcutaneous Dosing at The Alzheimer's Association International Conference (AAIC) 2023
Jul 6, 2023 11:21PM

312,667 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All